We use an extensive platform of biophysical techniques and capabilities to validate and characterise primary screening hits. These techniques include X-ray crystallography (Bruker D8 source in-house and regular time on multiple synchrotron facilities), NMR (Bruker 600 MHz with QCI-F cryoprobe and SampleJet autosampler), SPR (Biacore 8K and T200), ITC (Auto-iTC200), ASMS and thermal shift assay (TSA) amongst others. Our expertise in applying these and other methods to a wide range of drug discovery challenges enables us to rapidly and accurately guide the evolution of initial hits through to candidates.
Protein-observed NMR (PO-NMR)
Ligand-observed NMR (LO-NMR)
Macromolecular crystallography:
Small molecule crystallography